The FXa-inhibitor rivaroxaban has been shown to have anti-neoplastic synergistic effects with immune checkpoint inhibitors (ICIs) in a real-world cohort of patients with metastatic melanoma [65]. This evidence concerns the gene F10 and metastatic melanoma.